Drug Evaluation Committee 2012-17 Disclosure of Investigator Site Names in Public Clinical Trial Information
Related classification: subject recruitment
Initial release date: 2012.08
Revised release date: Mar. 2021
Question
Question 1
The publication of the names of Investigator Sites in clinical trial databases such as Clinical Trial.gov and jRCT does not fall under the "Guidelines for Providing Information for the Recruitment of Subjects for Clinical Trials" published by JPMA in November 2008, because the purpose is to provide information, not to recruit subjects. Is it correct to conclude that this is not applicable?
Question 2
We are planning to publish an outline of the clinical trial (purpose, planned acceptance period, main criteria for participation, method and duration of the trial, etc.) on the company website (hereinafter referred to as "website"). In this case, we would like to post links to Clinical Trial.gov, jRCT, etc. on our website.
JPMA's Opinion
Registration of clinical trials with the U.S. NIH's Clinical Trial.gov, the Japan Registry of Clinical Trials (jRCT), etc. (hereafter referred to as Clinical Trial.gov, etc.) is subject to the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Manufacturers and Associations of America (PhRMA), and the Pharmaceutical Manufacturers Association of America (PMA). The registration of clinical trials in the Japan Registry of Clinical Trials (hereinafter referred to as "Clinical Trial.gov, etc.") is conducted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), and the Japan Pharmaceutical Manufacturers Association (JPMA) as part of the Joint Guidelines for Disclosure of Clinical Trial Information via the Registry and Database of Clinical Trials, which is intended to provide the public with information about clinical trials. The JPMA is implementing the guidelines in the form of a joint statement to inform the public about clinical trials. On the other hand, the recruitment of subjects for clinical trials is mainly for the purpose of recruiting subjects by the Investigator Site conducting the relevant clinical trial, which is different from the purpose of disclosing information on clinical trials. In addition, posting a link to Clinical Trial.gov, etc. on the company website is considered part of the disclosure of information on clinical trials. Therefore, posting the name of the Investigator Site on Clinical Trial.gov, etc. and the link to Clinical Trial.gov, etc. on the company website do not constitute "providing information for recruiting subjects" as defined in the JPMA document "Guidelines for Providing Information for the Recruitment of Subjects for Clinical Trials. However, it is not considered to be "information for recruiting subjects" as defined by the Pharmaceutical Manufacturers Association of Japan.
However, when the name of the Investigator Site is posted as clinical trial information, it is anticipated that inquiries may be made directly to the Investigator Site by visitors to the site.
Reason for revision
In accordance with the issuance of "No. 0831 No. 9 of August 31, 2020, "Registration of Clinical Trial Implementation Status, etc." by the Pharmaceutical Affairs Agency of Japan, minor changes were made.